Overall market sentiment has been down on Crispr Therapeutics AG (CRSP) stock lately. CRSP receives a Bearish rating from InvestorsObserver Stock Sentiment Indicator.
Crispr Therapeutics AG has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on CRSP!
What is Stock Sentiment?
Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends.
Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down.
InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend.
Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.
What's Happening With CRSP Stock Today?
Crispr Therapeutics AG (CRSP) stock is trading at $69.87 as of 10:14 AM on Friday, Aug 19, a drop of -$2.28, or -3.16% from the previous closing price of $72.15. The stock has traded between $69.25 and $71.77 so far today. Volume today is light. So far 196,500 shares have traded compared to average volume of 1,473,210 shares.
To see InvestorsObserver's Sentiment Score for Crispr Therapeutics AG click here.
More About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Click Here to get the full Stock Report for Crispr Therapeutics AG stock.